Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials

TY - JOUR

T1 - Tapinarof Cream 1% Once Daily for Plaque Psoriasis

T2 - Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials

AU - Kircik, Leon

AU - Gold, Linda Stein

AU - Rosso, James Del

AU - Desai, Seemal R.

AU - Glick, Brad P.

AU - Sofen, Howard

AU - Tallman, Anna M.

AU - Rubenstein, David S.

AU - Fournier, Janine

AU - Brown, Philip M.

N1 - Funding Information: This study was funded by Dermavant Sciences, Inc. The authors thank the participating investigators, patients and their families, and colleagues involved in the conduct of the study. L.K. has served as a consultant/speaker/investigator/advisory board member for Abbott Laboratories, AbbVie, Ablynx, Aclaris, Acambis, Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Anaptys, Arcutis, Arena, Assos Pharma, Astellas Pharma US, Inc., Asubio, Bausch Health, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biogen-Idec, Biolife, Biopelle, BMS, Boehringer-Ingleheim, Breckinridge Pharma, Cassiopea, Centocor, Inc., Cellceutix, Cipher, Coherus, Colbar, Combinatrix, Connetics Corporation, Coria, Dermavant Sciences, Inc., Dermira, Dermik Laboratories, Dow Pharmaceutical Sciences, Inc., Dr. Reddy’s Lab, Dusa, Embil Pharmaceuticals, Eli Lilly, EOS, Exeltis, Ferndale Laboratories, Inc., Foamix, Ferrer, Galderma, Genentech, Inc., GlaxoSmithKline, PLC, Glenmark, Health Point, LTD, Idera, Incyte, Intendis, Innocutis, Innovail, Isdin, Johnson & Johnson, Kyowakirin, Laboratory Skin Care, Inc., LEO Pharma, L’Oreal, 3M, Maruho, Medical International Technologies, Merck, Medicis Pharmaceutical Corp., Merz, Nano Bio, Novartis AG, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, PediaPharma, Pfizer, Promius, PuraCap, PharmaDerm, QLT, Inc, Quinnova, Quatrix, Regeneron, Sanofi, Serono (Merck Serono International SA), SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, TolerRx, Triax, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort and ZAGE. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/ or has received grants from Arcutis, Amgen, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. J.D.R. is an advisor and research investigator for Dermavant Sciences, Inc. B.P.G. has served as an investigator/speaker/advisor for AbbVie, Brickell Biotech, Celgene, ChemoCentryx, Corrona Registry PSO, Corrona Registry AD, Dermavant Sciences, Inc, Dermira, Eli Lilly, Janssen, Novartis, Ortho Dermatologics, Pfizer, Prose Registry, Regeneron, Sanofi-Genzyme, Sun Pharmaceutical Industries, Inc. H.S. has served as scientific adviser and/or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Sciences Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Sun Pharma and UCB. A.M.T., D.S.R, J.F., and P.M.B. are employees of Dermavant Sciences, Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Contact Dr Leon Kircik at wedoderm@yahoo.com with questions or comments.

PY - 2022/3/4

Y1 - 2022/3/4

UR - http://www.scopus.com/inward/record.url?scp=85136271061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136271061&partnerID=8YFLogxK

U2 - 10.25251/skin.6.supp.7

DO - 10.25251/skin.6.supp.7

M3 - Comment/debate

AN - SCOPUS:85136271061

SN - 2574-1624

VL - 6

SP - s7

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 2

ER -